Details for Patent: 9,132,093

Which drugs does patent 9,132,093 protect, and when does it expire?

Patent 9,132,093 protects UCERIS and is included in one NDA.

This patent has twenty-six patent family members in seventeen countries.

Summary for Patent: 9,132,093

Title:	Controlled release and taste making oral pharmaceutical composition
Abstract:	Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Inventor(s):	Villa; Roberto (Lecco, IT), Pedrani; Massimo (Gignese, IT), Ajani; Mauro (Milan, IT), Fossati; Lorenzo (Milan, IT)
Assignee:	COSMO TECHNOLOGIES LIMITED (Dublin, IE)
Application Number:	13/585,190
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,132,093
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,132,093

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	UCERIS	budesonide	TABLET, EXTENDED RELEASE;ORAL	203634-001	Jan 14, 2013	AB	RX	Yes	Yes			Y

International Family Members for US Patent 9,132,093

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	251449
Australia	5680100
Canada	2377301
China	1173695
China	1355693
Germany	60005819